期刊文献+

妊娠期甲胎蛋白检测应用研究进展

Research progress of alpha-fetoprotein testing during pregnancy
在线阅读 下载PDF
导出
摘要 甲胎蛋白(AFP)是在人类胎儿血清中发现的一种血清糖蛋白。它是载体/运输分子,也是一种生长调节剂,参与免疫调控,在胚胎性分化发育过程中和雌性生殖系统发育发挥重要作用。多年以来在临床上,AFP是妊娠期21-三体综合征筛查的主要生物标志物。此外,近期研究证实,孕期AFP检测还可以在监测胎盘功能,预测妊娠合并症、早产、死胎、脑瘫、胎膜早破、妊娠不良结局,早期发现新生儿疾病等方面发挥作用。随着技术的发展AFP检测在妊娠期诊断中将会有更广阔的应用前景。 Alpha-fetoprotein(AFP)is a serum glycoprotein found of human fetus.It is a carrier/transport molecule and i growth regulator,and which involves in the immune regulation,and plays an important role in the development of embryonic sexual differentiation and in the development of the female reproductive system.Over the past decades,AFP has been used as the main clinical biomarker indicator in the screening of trisomy 21 syndrome during pregnancy.In addition,recently published studies have confirmed that AFP testing during pregnancy can also play roles in the monitoring the placental function,pregnancy complications,preterm delivery,stillbirth,perebral palsy,premature rupture of membranes,and adverse pregnancy outcomes,and in the detection of neonatal diseases early.With the development of technology,AFP testing will have a broader application in the diagnosis during pregnancy.
作者 周定杰 吴玉璘 杨月华 吕年青 梁爽 傅雅丽 孙丽洲 ZHOU Dingjie;WU Yulin;YANG Yuehua;LV Nianqing;LIANG Shuang;FU YaLi;SUN Lizhou(Jiangsu Health Development Research Center,NHC Contrace ptives Adverse Reaction Surevillance Center,Nanjing,Jiangsu Province,210036;The First Affiliated Hospital of Nanjing Medical University)
出处 《中国计划生育学杂志》 2023年第3期720-724,731,共6页 Chinese Journal of Family Planning
基金 江苏省科技厅创新能力建设计划(科技设施类)-省属公益类科研院所自主科研经费(BM2018033-3) 江苏省医学科研项目(M2021092) 江苏省卫生健康发展研究中心自主科研项目(JSHD2021061)。
关键词 产前筛查 甲胎蛋白 21-三体综合征筛查 生物标志物 Prenatal screening Alpha fetoprotein Trisomy 21 syndrome screening Biomarkers
作者简介 通信作者:孙丽洲,lizhou_sun@163.com。
  • 相关文献

参考文献2

二级参考文献45

  • 1Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). JMed Screen ,2003,10:56-104.
  • 2Wald N J, Rodeck C, Hackshaw AK, et al. SURUSS in perspective. BJOG,2004, 111:521-531.
  • 3Malone FD, Canick JA, Ball RH, et al. First-trimester or second- trimester screening, or both, for Down's syndrome. N Engl J Med, 2005, 353:2001-2011.
  • 4Wapner R, Thorn E, Simpson JL, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med, 2003, 349:1405-1413.
  • 5Nieolaides KH, Spencer K, Avgidou K, et al. Multicenter study of first-trimester screening for trisomy 2L in 75 821 pregnancies: results and estimation of the potential impaet of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gyneco1,2005, 25:221-226.
  • 6Merkatz IR, Nitowsky HM, Macri JN, et al. An association between low materual serum alpha-fetoprotein and fetal chromosome abnormalities. Am J Obstet Gynecol,198d, 148:886-894.
  • 7Wald N J, Kennard A, Hackshaw A, et al. Antenatal screening for Down's syndrome. J Med Screen,1997, 4:181-246.
  • 8Canick JA, Knight GJ, Palomaki GE, et al. Low seeond trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol,1988, 95:330-333.
  • 9Wald NJ, Watt HC, Hackshaw AK, Integrated screening fnr Down's syndrome on the basis of tests pertbrmed during the first and second trimesters. N Engl J Med, 1998, 341:461-467.
  • 10Tabor A, Philip J, Madsen M, et al. Randomized controlled trial of genetic amniocentesis in 4 606 low risk women. Lancet, 1986, 1 : 1287-1293.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部